Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Wow! Talk about at the buzzer. They hit their Q2 approval goal.
Let's see if we can execute on the timeline for starting the trial + interim data this year, then final data in Q1 next year!
(From their corporate presentation):
SBI-100 OE: PHASE 1
? Q1-22: Completion of GLP toxicology studies
? Q2-22: AUS Human Research Ethics Committee (HREC) approval to start Phase 1 study
? Q3-22: Phase 1 interim data
? Q1-23: Phase 1 final data
It's a good question, but a wide range as of now. Need to see what all actual charges, then will depend on lawyers and judge. Avtar has also been involved in other companies, so I expect the investigation to expand significantly.
Sucks for investors.
I hope he goes to prison for a long time. I sold out a while ago, but He f'd a lot of people. And they will be investigating other companies he's been a part of...there are multiple more.
Disgusting.
BOOM....If we can get some new eyeballs on SKYE, we should move positively.
https://ir.skyebioscience.com/news-events/press-releases/detail/112/skye-biosciences-thcvhs-demonstrates-superior
Sequire Conference today: 1. IOP data to be released before end of the quarter and 2. New competitive data (latanoprost + Rhopressa) to be released before end of quarter. With both expected to be positive, expecting a share price bump when announcement is made sometime in the next 70 days.
Head of Regulatory Affairs and Quality Assurance position just listed:
https://www.linkedin.com/jobs/view/2484364403
If you mean University of Mississippi, no. Skye will be funding the trials (unless they get some sort of Gov't grant/funding).
Good write up
Skye Bioscience Is Pursuing A New Kind Of Glaucoma Drug
https://finance.yahoo.com/news/skye-bioscience-pursuing-kind-glaucoma-140237389.html
You should try the world wide web. It has a lot of information.
Good article...nice find! Confirming clinical trial starting in Q3 2021 as stated in their last company update. EMBI may stick in this low trading range for a while longer, but looks exciting for late 2021...
I don't really care about ElSohly's papers...its the Ole Miss patents that EMBI has perpetual global licenses for that need to continue.
Also, Dr. Mahmoud ElSohly, our champion and leader of Cannabis projects at Ole Miss, is no longer listed on the EMBI scientific advisory board. Did Punit already F-up that relationship?
I agree. At least Dr. Murphy had incentive to drive the science forward. Now our (new) CEO just has his dad raise capital to pay his salary and fund his extracurricular habits.
I never said they'd uplist, I doubt they'll be able to...the Company Update said it.
Thanks again for making my point. Again.
They're financials are fook'd, the Dhillons are crooks. Raise, dilute, repeat. With this new share structure @ $4, they'd be over a billion dollar company. If EMBI ever starts to show value, they'll get snatched up before ever getting close to $4.
I love your passion, Lucky.
You're the Tard. Q3-2021.
Thanks supplying the data that we already knew for my reverse split "speculation".
Show me where they say Clinical Trials begin in 3 months. I would be ecstatic for that news. The Company Update reads Q32021.
Agree on all your opinions of the awfulness of a reverse split. It would ruin existing shareholders like me who have been in this for years.
I'm very familiar with the regs and requirements for uplisting on all exchanges. Anyone who plays in the OTC market should be intimately familiar with the multiple liquidity, reporting and financial requirements to uplist...
They actually filed an application with NYSE to uplist in 2015 (that went nowhere), a year after they executed the reverse merger to the OTC while they were still Nemus (NMUS) after their series B round. Mainly because NASDAQ is more strict + $4 share price requirement.
Did you even read the Company Update? How do you think they're going to uplist at 4 cents? Also, NASDAQ requires a mkt value of at least $45m. Clinical Trials have nothing to do with a reverse split or uplisting.
"The Company is considering an appropriate path to up-list to a major stock exchange in order to enable a broader spectrum of the investment market to participate in Emerald’s stock and also to enhance the recognition and profile of the company."
I suggest you read the whole update before you reply again. Your 2 free cut & pastes have been used.
Next year, that's right. To you that means Jan 1st (or any other idiot that doesn't read the whole update). If YOU READ the rest, you'll see clinical in Q32021 with data in 2022.
"The Company plans to initiate its first in-human clinical study for the treatment of glaucoma in Q32021 with data anticipated in early 2022. The study will consist of a single ascending dose (SAD) arm in healthy volunteers, followed by a multiple ascending dose (MAD) arm in healthy volunteers, and will also assess subjects with glaucoma and/or elevated IOP."
I fear a reverse split is in the future. Clinicals pushed out an entire year.
https://finance.yahoo.com/news/emerald-bioscience-provides-corporate-123000750.html
Good to see news, but additional patents won't move the needle, unfortunately. Patents are expected, required but not market movers. The only thing that will kick start this will be human trials...that's the next catalyst. Hopefully COVID hasn't pushed that further and they get started in the coming months.
Reposting this article. The IP they own and continue to build is spectacular. The waiting is a grind, but will eventually pay out...
"The two drug candidate formulations include a synthetic prodrug of tetrahydrocannabinol, commonly known as THC, the main psychoactive compound associated with marijuana, and a synthetic analog of cannabidiol another compound that is attracting widespread attention as a potential treatment for a variety of medical conditions. Both drug candidates are derivatives of the natural THC and CBD found in the cannabis plant.'
"The second drug candidate, the THC prodrug, is an inactive form of THC that becomes activated when absorbed into the body. Along with Emerald Bioscience, Ole Miss and ELI researchers developed a THC prodrug to treat glaucoma that can be absorbed through the tissues in the eye after a simple eyedrop application.
“Getting to this pivotal point took almost 10 years,” said Soumyajit Majumdar, professor of pharmaceutics and drug delivery and leader of the THC prodrug research team. “The Ole Miss and ELI research teams developed many iterations of the THC prodrug, balancing the characteristics of the compounds to come up with a molecule and an ophthalmic formulation that has the optimal characteristics to treat glaucoma effectively.”"
https://news.olemiss.edu/um-partners-emerald-bioscience-license-cannabis-derived-drugs/
$2mm direct offering, 8 million shares (+ warrants).
Agree. We already know the preclinicals + animal studies show NB1111 is superior to Latanoprost and Timolol. This is all good news EMBI continues to present to the market, but preIND is the next catalyst.
Monday's presentation
http://wsw.com/webcast/hcw5/embi/index.aspx
Interview with $EMBI
Watch "Emerald Bioscience, Inc. (OTCQB: EMBI) | SNN Network" on YouTube
Agree = Manipulation! Small lots being sold to drive the price into the low 30's, then bigger buys on the upswing...scallywags! PreIND meeting has not happened yet.
Agree. They have access to enough capital to execute preIND + start the human trials for NB1111. Let's get this puppy going to the next stage.
The technology has been in the works for a while. Multiple chambers of the eye is huge. Slowly building more and more value with these milestones.
Emerald Bioscience’s NB2222 Exhibits Superior Ocular Permeation into Multiple Compartments of the Eye Compared to Cannabidiol
https://finance.yahoo.com/news/emerald-bioscience-nb2222-exhibits-superior-120000723.html
EMBI's video from today's CannaStocks Conference - I highly recommend watching it. CEO Brian Murphy gives a 20 minute overview of current status of the company and discusses NB1111 in detail. You'll have to login or register, but can watch a replay 'on demand'. Good stuff:
https://www.virtualinvestorconferences.com/resources
Citron...a well know short artist and company slammer put out a nasty piece against Village Farms / Emerald Health today. Slamming Avtar Dhillon (head of Emerald + Chairman of EMBI) as a scam artist. EMBI continuing to execute all all cylinders and potential as a pharma is significant. Slam piece may be causing some of this short term impact. Nemus core before Emerald got involved is still there, story the same. Long and strong...
https://seekingalpha.com/news/3451148-citron-expects-freefall-village-farms